<SEC-DOCUMENT>0001157523-22-001256.txt : 20220922
<SEC-HEADER>0001157523-22-001256.hdr.sgml : 20220922
<ACCEPTANCE-DATETIME>20220922161701
ACCESSION NUMBER:		0001157523-22-001256
CONFORMED SUBMISSION TYPE:	6-K
PUBLIC DOCUMENT COUNT:		2
CONFORMED PERIOD OF REPORT:	20220922
FILED AS OF DATE:		20220922
DATE AS OF CHANGE:		20220922

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Nanobiotix S.A.
		CENTRAL INDEX KEY:			0001760854
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				000000000
		STATE OF INCORPORATION:			I0
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		6-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-39777
		FILM NUMBER:		221259412

	BUSINESS ADDRESS:	
		STREET 1:		60 RUE DE WATTIGNIES
		CITY:			PARIS
		STATE:			I0
		ZIP:			75012
		BUSINESS PHONE:		33140260470

	MAIL ADDRESS:	
		STREET 1:		60 RUE DE WATTIGNIES
		CITY:			PARIS
		STATE:			I0
		ZIP:			75012
</SEC-HEADER>
<DOCUMENT>
<TYPE>6-K
<SEQUENCE>1
<FILENAME>a52923338.htm
<DESCRIPTION>NANOBIOTIX S.A. 6-K
<TEXT>
<html>
  <head>
    <title></title>
    <!-- Licensed to: Business Wire
         Document created using EDGARfilings PROfile 8.4.0.0
         Copyright 1995 - 2022 Broadridge -->
  </head>
<body bgcolor="#ffffff" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left; color: #000000;">
  <font style="font-family: 'Times New Roman',Times,serif;">
  </font>
  <div>
    <div style="font-family: 'Times New Roman',Times,serif;"><br>
    </div>
    <div style="text-align: center; font-family: 'Times New Roman',Times,serif; font-size: 16pt; font-weight: bold;">UNITED STATES</div>
    <div style="text-align: center; font-family: 'Times New Roman',Times,serif; font-size: 16pt; font-weight: bold;">SECURITIES AND EXCHANGE COMMISSION</div>
    <div style="text-align: center; font-family: 'Times New Roman',Times,serif; font-weight: bold;">Washington, D.C. 20549</div>
    <div style="font-family: 'Times New Roman',Times,serif;">&#160;</div>
    <div style="text-align: center; font-family: 'Times New Roman',Times,serif; font-size: 16pt; font-weight: bold;">FORM 6-K</div>
    <div style="font-family: 'Times New Roman',Times,serif;">&#160;</div>
    <div style="text-align: center; font-family: 'Times New Roman',Times,serif; font-weight: bold;">Report of Foreign Private Issuer</div>
    <div style="text-align: center; font-family: 'Times New Roman',Times,serif; font-weight: bold;">Pursuant to Rule 13a-16 or 15d-16</div>
    <div style="text-align: center; font-family: 'Times New Roman',Times,serif; font-weight: bold;">of the Securities Exchange Act of 1934</div>
    <div style="font-family: 'Times New Roman',Times,serif;">&#160;</div>
    <div style="text-align: center; font-weight: bold;">Date of Report: 09/22/2022</div>
    <div style="font-family: 'Times New Roman',Times,serif;">&#160;</div>
    <div style="text-align: center; font-weight: bold;">Commission File Number: 001-39777</div>
    <div style="font-family: 'Times New Roman',Times,serif;">&#160;</div>
    <div style="text-align: center; font-family: 'Times New Roman',Times,serif; font-size: 16pt; font-weight: bold;">Nanobiotix S.A.</div>
    <div style="text-align: center; font-weight: bold;">(Exact Name of Registrant as Specified in its Charter)</div>
    <div style="font-family: 'Times New Roman',Times,serif;">&#160;</div>
    <div style="text-align: center; font-weight: bold;">60 Rue de Wattignies</div>
    <div style="text-align: center; font-weight: bold;">75012 Paris, France</div>
    <div style="text-align: center; font-family: 'Times New Roman',Times,serif; font-weight: bold;">(Address of principal executive office)</div>
    <div style="font-family: 'Times New Roman',Times,serif;">&#160;</div>
    <div>Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F:</div>
    <div style="font-family: 'Times New Roman',Times,serif;">&#160;</div>
    <div style="text-align: center;">Form 20-F &#9746; Form 40-F &#9744;</div>
    <div style="font-family: 'Times New Roman',Times,serif;">&#160;</div>
    <div>Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): &#9744;</div>
    <div style="font-family: 'Times New Roman',Times,serif;">&#160;</div>
    <div>Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): &#9744;</div>
    <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" id="DSPFPageBreakArea">
      <div style="page-break-after: always;" id="DSPFPageBreak">
        <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
    </div>
    <div style="font-weight: bold;"><u>EXHIBIT INDEX</u></div>
    <div style="font-weight: bold;"><u> <br>
      </u></div>
    <table cellspacing="0" cellpadding="0" id="zdfeb25282cef4784b0c3995f62065f0e" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; border-collapse: collapse; text-align: left; color: #000000;">

        <tr>
          <td nowrap="nowrap" style="width: 5.51%; vertical-align: bottom; font-family: 'Times New Roman',Times,serif; font-weight: bold;">
            <div>Exhibit</div>
          </td>
          <td nowrap="nowrap" style="width: 94.42%; vertical-align: bottom; font-family: 'Times New Roman',Times,serif;">
            <div style="font-weight: bold;">Title</div>
          </td>
        </tr>
        <tr>
          <td style="width: 5.51%; vertical-align: middle; font-family: 'Times New Roman',Times,serif;">&#160;</td>
          <td style="width: 94.42%; vertical-align: middle; font-family: 'Times New Roman',Times,serif;">&#160;</td>
        </tr>
        <tr>
          <td nowrap="nowrap" style="width: 5.51%; vertical-align: top; font-family: 'Times New Roman',Times,serif;">
            <div><a href="a52923338ex99_1.htm">99.1</a></div>
          </td>
          <td style="width: 94.42%; vertical-align: top; font-family: 'Times New Roman',Times,serif;">
            <div><a href="a52923338ex99_1.htm">Press Release, dated September 22, 2022</a></div>
          </td>
        </tr>

    </table>
    <div style="font-family: 'Times New Roman',Times,serif; font-weight: bold;"> <br>
    </div>
    <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" id="DSPFPageBreakArea">
      <div style="page-break-after: always;" id="DSPFPageBreak">
        <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
    </div>
    <div style="text-align: center; font-weight: bold;">SIGNATURES</div>
    <div style="font-family: 'Times New Roman',Times,serif;">&#160;</div>
    <div>Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned,
      thereunto duly authorized.</div>
    <div style="font-family: 'Times New Roman',Times,serif;">&#160;</div>
    <table cellspacing="0" cellpadding="0" border="0" id="z888a329e7ed24d51b7ddcdb788671901" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; border-collapse: collapse; text-align: left; color: #000000;">

        <tr>
          <td style="width: 50%; vertical-align: top; font-family: 'Times New Roman',Times,serif;">&#160;</td>
          <td style="vertical-align: top;" colspan="2">
            <div style="font-weight: bold;">NANOBIOTIX S.A.</div>
            <div>(Registrant)</div>
          </td>
          <td style="vertical-align: top; width: 10%;" colspan="1">&#160;</td>
        </tr>
        <tr>
          <td style="width: 50%; vertical-align: middle; font-family: 'Times New Roman',Times,serif;">&#160;</td>
          <td style="width: 3%; vertical-align: middle; font-family: 'Times New Roman',Times,serif;">&#160;</td>
          <td style="width: 37%; vertical-align: middle; font-family: 'Times New Roman',Times,serif;">&#160;</td>
          <td style="width: 10%; vertical-align: middle; font-family: 'Times New Roman',Times,serif;" colspan="1">&#160;</td>
        </tr>
        <tr>
          <td style="width: 50%; vertical-align: middle; font-family: 'Times New Roman',Times,serif;">&#160;</td>
          <td style="width: 3%; vertical-align: middle; font-family: 'Times New Roman',Times,serif;">&#160;</td>
          <td style="width: 37%; vertical-align: middle; font-family: 'Times New Roman',Times,serif;">&#160;</td>
          <td style="width: 10%; vertical-align: middle; font-family: 'Times New Roman',Times,serif;" colspan="1">&#160;</td>
        </tr>
        <tr>
          <td style="width: 50%; vertical-align: bottom; font-family: 'Times New Roman',Times,serif; padding-bottom: 2px;">
            <div>09/22/2022</div>
          </td>
          <td style="width: 3%; vertical-align: top; font-family: 'Times New Roman',Times,serif; padding-bottom: 2px;">
            <div>By:</div>
          </td>
          <td style="width: 37%; vertical-align: bottom; border-bottom: 2px solid rgb(0, 0, 0);">
            <div>
              <div style="font-family: 'Times New Roman',Times,serif;">/s/ Bart Van Rhijn</div>
            </div>
          </td>
          <td style="width: 10%; vertical-align: top; padding-bottom: 2px;" colspan="1">&#160;</td>
        </tr>
        <tr>
          <td style="width: 50%; vertical-align: top; font-family: 'Times New Roman',Times,serif;">&#160;</td>
          <td style="width: 3%; vertical-align: top; font-family: 'Times New Roman',Times,serif;">&#160;</td>
          <td style="width: 37%; vertical-align: top; font-family: 'Times New Roman',Times,serif;">
            <div>Bart Van Rhijn</div>
          </td>
          <td style="width: 10%; vertical-align: top; font-family: 'Times New Roman',Times,serif;" colspan="1">&#160;</td>
        </tr>
        <tr>
          <td style="width: 50%; vertical-align: top; font-family: 'Times New Roman',Times,serif;">&#160;</td>
          <td style="width: 3%; vertical-align: top; font-family: 'Times New Roman',Times,serif;">&#160;</td>
          <td style="width: 37%; vertical-align: top; font-family: 'Times New Roman',Times,serif;">
            <div>Chief Financial Officer</div>
          </td>
          <td style="width: 10%; vertical-align: top; font-family: 'Times New Roman',Times,serif;" colspan="1">&#160;</td>
        </tr>

    </table>
    <div style="font-family: 'Times New Roman',Times,serif;"><br>
    </div>
  </div>
  <font style="font-family: 'Times New Roman',Times,serif;">
  </font>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>a52923338ex99_1.htm
<DESCRIPTION>EXHIBIT 99.1
<TEXT>
<html>
  <head>
    <title></title>
    <!-- Licensed to: Business Wire
         Document created using EDGARfilings PROfile 8.4.0.0
         Copyright 1995 - 2022 Broadridge -->
  </head>
<body bgcolor="#ffffff" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left; color: #000000;">
  <div style="text-align: right;"><font style="font-weight: bold;">Exhibit 99.1</font><br>
  </div>
  <div style="text-align: right;"><font style="font-weight: bold;"> <br>
    </font></div>
  <div>
    <div class="bw-release">
      <h1 style="text-align: center; list-style-position: inside;FONT-SIZE: 14pt;"> <b>Nanobiotix to Announce Half Year 2022 Financial Results on September 28, 2022</b> </h1>
      <div class="bw-release-subhead">
        <p style="text-align: center; list-style-position: inside;"><b> <b><i>Conference Call and Webcast to be Held at 8:00 AM ET / 2:00 PM CET on September 29, 2022</i></b> </b></p>
      </div>
      <div class="bw-release-body">
        <div class="bw-release-table-js bw-release-story">
          <p>PARIS &amp; CAMBRIDGE, Mass.--(BUSINESS WIRE)--September 22, 2022--Regulatory News: </p>
          <p> NANOBIOTIX (Euronext: NANO &#8211;&#8211; NASDAQ: NBTX &#8211; the &#8216;&#8216;<b>Company</b>&#8217;&#8217;), a late-clinical stage biotechnology company pioneering physics-based approaches to expand treatment possibilities for patients with cancer, today announced that it will
            report its financial results for half-year ending June 30, 2022, on Wednesday, September 28, 2022, after the close of the US market. </p>
          <p> The announcement will be followed by a conference call and live audio webcast on Thursday, September 29, 2022, at 8:00 AM ET / 2:00 PM CET. During the call, Laurent Levy, chief executive officer, and Bart Van Rhijn, chief financial officer,
            will briefly review the Company&#8217;s half-year results and provide an update on business activities before taking questions from participants. </p>
          <p> A live webcast of the call may be accessed by visiting the investors section of the company's website at www.nanobiotix.com. Participants may register for the call here. They will be able to join the call via dial-in or one-click dial-out. It
            is recommended to join 10 minutes prior the event start. <br>
            Participants are invited to email their questions in advance to investors@nanobiotix.com. </p>
          <p> A replay of the webcast will be available shortly after the conclusion of the call and will be archived on the company's website. </p>
          <p style="text-align: center; list-style-position: inside;"> *** </p>
          <p> <b>About NANOBIOTIX</b> </p>
          <p> Nanobiotix is a late-stage clinical biotechnology company pioneering disruptive, physics-based therapeutic approaches to revolutionize treatment outcomes for millions of patients; supported by people committed to making a difference for
            humanity. The company is leveraging its proprietary nanoparticle platform, including its lead product candidate, radiotherapy-activated NBTXR3, to develop a pipeline of therapeutic options designed to enhance local and systemic control of solid
            tumors with an initial focus on the treatment of head and neck cancers. </p>
          <p> For more information about Nanobiotix, visit us at www.nanobiotix.com or follow us on LinkedIn and Twitter. </p>
        </div>
        <div class="bw-release-contact">
          <h2 style="FONT-SIZE: 14pt;">Contacts</h2>
          <p> <i>Nanobiotix</i> </p>
          <p> <b>Communications Department </b><br>
            <i>Brandon Owens </i><br>
            <i>VP, Communications </i><br>
            +1 (617) 852-4835 <br>
            contact@nanobiotix.com </p>
          <p> <b>Investor Relations Department </b><br>
            <i>Kate McNeil </i><br>
            <i>SVP, Investor Relations </i><br>
            +1 (609) 678-7388 <br>
            investors@nanobiotix.com </p>
          <p> <i>Media Relations</i> </p>
          <p> FR &#8211; <b>Ulysse Communication </b><br>
            Pierre-Louis Germain <br>
            + 33 (0) 6 64 79 97 51 <br>
            plgermain@ulysse-communication.com </p>
          <p> Global &#8211; <b>LifeSci Advisors </b><br>
            Ligia Vela-Reid <br>
            +44 (0) 7413825310 <br>
            Lvela-reid@lifesciadvisors.com </p>
        </div>
      </div>
    </div>
    <font style="font-weight: bold;"> </font></div>
</body>
</html>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
